Clinical Utilization Pattern of Multiple Strengths of Glimepiride and Metformin Fixed Dose Combinations in Indian Type 2 Diabetes Patients.

格列美脲 医学 二甲双胍 糖尿病 2型糖尿病 磺酰脲 体质指数 内科学 内分泌学
作者
Unnikrishnan Ag,Kaushik Pandit,Jesso George,Satchi Venkataraman,Abhyankar Mv
出处
期刊:PubMed [National Institutes of Health]
卷期号:68 (7): 57-61 被引量:6
链接
标识
摘要

In Indian clinical set-up, modern sulfonylurea, particularly glimepiride is still preferred as an add-on to metformin due to its efficacy, safety and cost effectiveness. In view of this, a case-based questionnaire survey was conducted to analyze the clinical utility of multiple strengths of glimepiride and metformin fixed dose combination in type 2 diabetes mellitus (T2DM).The case-based questionnaire survey was conducted with 174 health care professionals across India to assess the use of glimepiride and metformin fixed dose combination according to age, duration of diabetes, body mass index (BMI), diabetes complications, concomitant medications like insulin, and statin.Overall, data from 2248 patients taking multiple strengths of glimepiride and metformin fixed dose combination were analyzed. All the doses were prescribed across all the age groups and irrespective of duration of diabetes. Overall, 1429 diabetes patients had body mass index (BMI) ≥25 kg/m2, among which 1176 (81.6%) patients were receiving combination of glimepiride 1 or 2 mg and metformin 500 or 850 or 1000 mg. Glimepiride and metformin fixed dose combinations were among the preferred choices in various complications like neuropathy, retinopathy, nephropathy, peripheral vascular disease, diabetic foot and cardiovascular disease. Insulin and statins were co-prescribed in 17.3% and 28.8% patients, respectively. Hypoglycemic episodes were reported in only a minority of patients, even with higher doses of glimepiride and metformin fixed dose combinations.Multiple strengths of glimepiride and metformin fixed dose combinations are beneficial in T2DM, irrespective of age, duration of diabetes, BMI, diabetes complications, use of concomitant medications such as insulin and statin. Glimepiride and metformin fixed dose combinations were not associated with a significant risk of hypoglycemia.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
我不会科研完成签到,获得积分10
刚刚
传奇3的应助被LYH采纳,获得10
刚刚
脑洞疼的应助被LYH采纳,获得10
刚刚
菜cc发布了新的文献求助10
1秒前
2秒前
滕皓轩发布了新的文献求助30
2秒前
2秒前
yan发布了新的文献求助10
2秒前
含蓄的之云完成签到,获得积分20
2秒前
3秒前
3秒前
缥缈巧蕊发布了新的文献求助10
3秒前
3秒前
4秒前
朱雅宁完成签到,获得积分10
4秒前
4秒前
5秒前
suhang2024发布了新的文献求助10
5秒前
领导范儿的应助被优美的易真采纳,获得10
5秒前
Twenni发布了新的文献求助10
5秒前
zl6发布了新的文献求助10
5秒前
明天发布了新的文献求助10
5秒前
善莫大焉发布了新的文献求助10
5秒前
6秒前
Quentin完成签到,获得积分10
7秒前
7秒前
米豆完成签到,获得积分10
8秒前
nalanfu完成签到,获得积分10
8秒前
patato1101发布了新的文献求助10
8秒前
jiaTS完成签到 ,获得积分10
8秒前
挚友发布了新的文献求助10
9秒前
张伟平发布了新的文献求助10
9秒前
erle3完成签到,获得积分10
9秒前
Orange的应助被积极剑通采纳,获得10
9秒前
JamesPei的应助被时叙采纳,获得10
10秒前
tiam完成签到,获得积分10
10秒前
沈同学完成签到,获得积分10
11秒前
Jun的应助被LYH采纳,获得10
11秒前
null的应助被动听的笑南采纳,获得10
11秒前
彭于晏的应助被伊布采纳,获得10
12秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
John McDowells Bildungstheorie 800
八旗制度の研究 600
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
Monte Cassino in the Middle Ages Volume I 310
JUSTIFICATION OF SMALL-SCALE MODELS: AN INDUSTRY PERSPECTIVE 300
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8156693
求助须知:如何正确求助?哪些是违规求助? 9552815
关于积分的说明 21711665
捐赠科研通 7745741
什么是DOI,文献DOI怎么找? 3426606
关于科研通互助平台的介绍 2551406
邀请新用户注册赠送积分活动 2470452